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ABSTRACT
Damage to the skin, subcutaneous tissues and blood vessels are among themost common health harms related to injecting
drug use. From a limited range of early reports of injecting‐related skin and soft tissue damage there is now an increasing
literature relating to new drugs, newcontaminants and problems associated with unsafe injection practices. Clinical issues
range from ubiquitous problems associated with repeated minor localised injection trauma to skin and soft tissue and in-
fections around injection sites, to systemic blood infections and chronic vascular disease. The interplay of limited availabil-
ity and access to sterile injecting equipment, poor injecting technique, compromised drug purity, drug toxicity and difficult
personal and environmental conditions give rise to injection‐related health harms. This review of injecting‐related skin,
soft tissue and vascular damage focuses on epidemiology and causation, clinical examination and investigation, treatment
and prevention.
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INTRODUCTION
Injection drug use, if practiced unsafely, can be an ex-
tremely harmful mode of non‐medical drug use. Once
the skin has been damaged or breached problems can
arise at the site of injection, in and beneath the skin, in
the blood vessel that has been penetrated, in the
subcutaneous fascia and muscle tissue and at remote
sites in distant organs in the body. Blood vessels form
part of the structure of all tissues and organs in the body
and are, therefore, the entry point for contaminated
products or foreign bodies to be introduced into organs
such as the lungs, kidneys, the heart, brain or liver but
also into muscle and bone tissue. Many subsequent prob-
lems are because of bacterial, viral or fungal infections
but drug toxicity, irritants and contaminants can also
cause aseptic damage to all these organs and structures.
Repeated trauma to vessels gives rise to superficial or
deep damage.
Description of blood‐borne viruses, bacterial sepsis and
contamination, endocarditis, and rarer infectious condi-
tions (i.e. candidal endophthalmitis, deep infections in
end organs and internal toxic effects of micro‐organisms
and contaminants), will be explored elsewhere in this
series. In this article, we will address injecting‐related skin
and soft tissue and vascular infections (SSTVI) and other
issues affecting blood vessels, with a focus on identification
and treatment of common presentations and their
sequalae, as well as issues related to engagingmarginalised
populations with care.
We shall overview SSTVIs and other vascular damage,
with a focus on epidemiology and causation, clinical
examination and investigation, treatment and prevention.
EPIDEMIOLOGY
Blood vessel and vascular damage can be relatively super-
ficial but can also lead to severe infections distal to the
injection site. SSTVIs, sometimes referred to as cutaneous
injection‐related infections (CIRI), are infections of the
surface of the skin or subcutaneous tissues causing
damage. These problems are the most reported
injection‐related injury with wide geographical variation
in lifetime prevalence. Due, in part, to a policy and
practice focus on blood‐borne viruses such as HIV and
hepatitis C among people who inject drugs (PWID),
they have been described as a ‘hidden epidemic of suffer-
ing’ [1].
Reports of injection‐related injury show a range of
problems and frequencies in different geographical
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localities [2]. Lifetime prevalence is reported to range from
6% (Australia) to 69% (Ireland) [3]. Hospitalisation for re-
lated complications are high with 49% of hospital admis-
sions in PWID being related to an SSTVI, over a 4‐year
period in Vancouver and up to 10% of PWID in the
United Kingdom reporting SSTVI‐related admissions per
year [4–8]. Other studies show a lifetime prevalence of
injecting complications among PWID ranging from
(0.5–12%) including sepsis (2–10%), bone and joint infec-
tions (0.5–2.0%), and thrombosis and emboli (3–27%)
[3,4]. Themajority of hospital admissionsmay be avoidable
and are often related to delays in access to simple interven-
tions in the community and suboptimal health care
facilities targeted at PWIDs [3].
SSTVIs among PWID costs the National Health Service,
in England, an estimated £47 million annually and inten-
sive care admission is common [5]. Severity and frequency
of an SSTVI is variable in geographical location and
individual situation depending on multiple factors and
associated health and social problems [6–10]. Differences
in drugmarkets, administration practices, service availabil-
ity and other local factorsmay all influence the appearance
and patterns of SSTVIs. Examples of other situations exac-
erbating vascular problems are fragmented drug supply
chains, limited provision of injecting equipment and envi-
ronments hostile to drug use such as custody situations.
The nature of the drug and material injected is impor-
tant. Preparations differ in their solubility and conse-
quently their suitability for injection. Types of heroin used
vary from country to country. Powder heroin from South
East Asia is most common in the United Kingdom and
Europe whereas black tar heroin, a resinous low grade type
from Mexico and South America, is more common in the
part of the United States andwhite ‘Chinese’ heroin is com-
mon in Australia. The heroin common in Oceania is easily
dissolved and prepared for injection but less used as a
smoked product. The United States seems to be divided into
east and west when it comes to availability and quality of
heroin, powder from Columbia being the most available
type in the east side and black tar from Mexico in the west
[11,12]. These variations in injecting materials have impli-
cations for the methods of injection solution preparation
and the associated impact on vascular sites [13].
Skin and vascular problems tend to impact the most
marginalised, those who are homeless or unstably housed,
people living with multi‐morbidities and those who are
economically insecure. Women who inject drugs are dis-
proportionately impacted with power relations playing an
influence (women may be less likely to be in control of
the injection preparation and administration process)
[14]. The stigma, shame, pain, unpleasant odour and mo-
bility restrictions associated with complications such as
chronic leg ulcers, can restrict social integration, access
to care and the possibility of accumulating recovery capital,
therefore exacerbating and entrenching social exclusion.
Homelessness, lack of safe or private injecting spaces, lim-
ited access to harm reduction information and equipment
or hygiene and cleaning facilities can all exacerbate risks
of contamination and unsafe injecting technique. In this
way, injecting practices, and the environments and social
relations in which they take place interplay to determine
injection‐related health harms.
CLINICAL PRESENTATION, ACUTE AND
CHRONIC CONDITIONS
Injection‐related medical problems can be related to sev-
eral factors: lack of skin and hand hygiene, trauma to the
skin or subcutaneous tissues, the use of non‐sterile or
shared equipment and contamination and toxicity of the
substances injected.
Damage can occur during or after intravenous injection
causingphlebitis, inflammationor infection, suchasa local-
ised sore or abscess. These problems are characterised by
swelling, irritation and pain or, if clotting or thrombosis oc-
curs,byhardtenderswellings.Longtermpersistent injecting
into superficial vein can cause fibrosis of the vein leading to
subcutaneous, palpable, swellings at the sites of valves or
around injection sites leading to subsequent loss of patency.
Skin lesions such as hypodermitis are indurated chronic
ulcerated lesions related to venous insufficiency. ‘Puffy
hands’ result from longstanding injecting into veins on the
dorsumof thehandandchronic lymphaticdamage [15,16].
Folliculitis, cellulitis and abscesses are sometimes
comparatively trivial and self‐limiting but not infrequently
require medical and hospital interventions and occasion-
ally lead to septicaemia, tissue sepsis and infection such
as endocarditis [17].
Chronic venous insufficiency or unresolved infection
can lead to ulceration at, and distal to, injection sites such
as the groin. These open wounds can be extensive, pene-
trating and frequently become infected. They are often dif-
ficult to manage and slow to heal.
Subcutaneous bacterial infections leading to superficial
erysipelas or deeper cellulitis present as painful, swollen red
areas often spreading via the lymphatic system. This can be
associated with fever, rigors and systemic symptoms of irri-
tability confusion and vomiting [18,19]. Untreated, dehy-
dration can lead to sepsis, shock, acute renal injury and
the requirement for admission to hospital and occasionally
to intensive care treatment.
Localised bleeding from an injection site or into soft tis-
sues can arise from traumatic injecting practice or indicate
an underlying condition such as liver failure or, rarely, a
bleeding disorder. Penetration of an artery by accident
may result in more serious haemorrhage manifesting as
bright red blood, soft tissue swelling and pain at, or distal
to, the injection site.
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Whereas injecting into a vein in the hand or upper limb
may result in damage and introduction of infection, injec-
tion into muscle or deeper vein is potentially more damag-
ing. Femoral or neck veins are used preferentially in some
places [20,21]. Longer term injecting into a femoral vein
can give rise to a sinus formation, establishing a track with
new skin lining (Fig. 1).
Damage or trauma to a deep vein such as the femoral
vein can result in a deep vein thrombosis causing swelling
of the limb and general pain in the area. Dislodgement and
movement of a ch bc lot or part of a clot, known as an em-
bolus, from the original site might allow transmission of
this material to the heart and from there to the lungs caus-
ing a pulmonary infarctionmanifested by sharp chest pain,
breathlessness or sudden death. Injecting into subcutane-
ous tissues or muscle is also common and damage, when
it occurs at these sites, may be locally problematic or lead
to systemic problems. More dangerous and rare infections
include necrotising fasciitis manifesting as a dramatic,
painful, swollen ulcerated area caused by contamination
of injecting materials with a combination of anaerobic
and aerobic organisms [22,23].
Arterial problems are less frequent than venous but
have, potentially, more damaging consequences. Variations
in injecting behaviours such as injecting into open wounds
or use of unusual site for the injection exist and may com-
plicate recovery and obscure causation.
Arterial spasm and stroke because of stimulants may
occur because of haemorrhage or thrombosis or vaso-
spasm. The drug type may be important, cerebral haemor-
rhage being implicated more with methamphetamine and
cocaine and stroke caused by vasospasm with Ecstasy
[24–29].
CAUSAL MECHANISMS
The most prominent and available sites for injection into a
vein are usually in the cubital fossa or on the dorsal surface
of the hands. Surface markings and visibility of veins are
more variable than the arterial system but conform to a
roughly familiar pattern throughout the body. Females
have the same vascular architecture but less surface visibil-
ity because of greater subcutaneous soft tissue adipose
tissue due in part to physiology. Body mass index (BMI)
and gender may be significant factors in accessing veins
[30,31].
In both sexes, difficulty in identifying and accessing a
suitable vein for injection can lead to the use of other sites
such as the femoral vein and veins on the legs or foot and
the external jugular vein. Less commonly, often in
Figure 1 Femoral vein sinus from longstanding injecting [Colour figure can be viewed at wileyonlinelibrary.com]
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desperation, veins in other parts of the body such as the
scalp, breast or penis can be used. Choice of injecting site
is determined by multiple factors but with care, a single
vessel can sometimes be used for many years. Over a
prolonged period of injecting, however, peripheral veins
may become thrombosed, painful or obstructed leading to
the use of sites in areas other than the arm.
The need for covert usemay result in use of a choice of a
lower limb vein and the femoral vein is the largest andmost
easily identified by its proximity to the pulsation of the
femoral artery, which can usually be palpated in the groin.
The anatomyof the femoral vein is important because it
is closely situated next to the femoral artery and nerve
(Fig. 2). This proximity leads to some of the more serious
complications of injecting such as bleeding, thrombosis
or, when material is injected into an artery by mistake
to arterial insufficiency, arteriovenous fistula, aneurysm
formation and damage to the supply of oxygenated blood
to the limb. Rarely, injecting into a nerve can result in
acute or longer standing neuropathic pain.
Poor hygiene when preparing the injection site is com-
monly the cause of skin irritation and the introduction of
infection. When infection is present the bacteria involved
are, most commonly, a variety gram‐positive bacteria such
as streptococcus and staphylococcus (and occasionally
the resistant variety methicillin‐resistant Staphylococcus
aureus) [32–35]. These can be the cause of folliculitis,
cellulitis, sepsis and septicaemia.
Less common, and usually occurring in clusters
because of contaminated batches of heroin, are the
gram‐positive gas and toxin‐producing bacteria varieties
such as clostridium and the spore formingBacillus anthracis
that are encountered when there is gross contamination of
materials from soil or animal materials. These outbreaks
tend to be severe and are associated with considerable
morbidity and mortality but are usually self‐limiting and
geographically quite localised [22,23,36–38].
Unusual infections such as anthrax and clostridial
types might initially appear to be a comparatively trivial
skin or subcutaneous problem but can rapidly escalate
to systemic sepsis, necrotising fasciitis, tissue or organ
damage.
Injection sites contaminated with anaerobic organisms
are more likely to become a problem when the injection is
subcutaneous or intramuscular where oxygen levels are
lower and anaerobic infections flourish.
Because injected materials are introduced into the ve-
nous system in the body drugs and contaminants, sterile
or septic, either soluble or in particulate form, will be trans-
mitted first to the right side of the heart and then to the
lungs where the blood goes for reoxygenation. The lungs
can act as a filter for insoluble materials larger than micro-
organisms and form a locus for any foreign material intro-
duced into the circulation. Oral preparations consist largely
of fillers such as talc or starch and this insoluble particulate
matter accumulates in the pulmonary capillaries. These
can provoke a foreign‐body giant cell reaction, potentially
causing thrombosis and fibrosis, and at longer term, pul-
monary hypertension. [39] Thrombosis can occur in femo-
ral, iliac and, more rarely, inferior vena cava veins.
Although the most common drugs of injection are opi-
ates and stimulants, there are reports of damage caused by
injection of prescription drugs not manufactured for injec-
tion. These include pharmaceuticals such as benzodiaze-
pines, methadone tablets, oxycodone, morphine sulphate,
methylphenidate and antidepressants [27,40]. Drugs
Figure 2 Anatomy of femoral area showing close proximity of vein, artery and nerve [Colour figure can be viewed at wileyonlinelibrary.com]
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prepared in pill, powder or capsule form for oral use are
likely to increase vascular damage if used by injectionwith-
out adequate filtration to remove large particulates. There
are some drugs such as such as mephedrone and metha-
done injectable solution that can cause vein damage be-
cause of their irritant quality. Cocaine is damaging to
blood vessels when injected, through its irritant, anaes-
thetic and vasoconstrictive properties. This is compounded
by the increased frequency of its use due to its short dura-
tion of action. Crack cocaine requires acidification to ren-
der it soluble for injection—overuse of acidifier can cause
additional venous problems [41].
Superficial infections can be a commonplace experience
among PWID. Considerable barriers tomedical care access,
normalisation of pain and limited perceptions of severity
mean that self‐management is common [42].
Contaminated drug preparation and reused injecting
equipment are important factors informing skin and
tissue damage. Widespread low‐threshold availability of
sterile needle and syringes is critical to reduce
injection‐related risk practices and infections. Service
restrictions and closures because of the COVID‐19 pan-
demic highlight the need to invest and support innovative
modes of distribution, including street outreach, vending
machine provision and secondary supply through peer
networks [43].
Injecting culture and practice are geographically vari-
able. Brown ‘Afghani’ powder heroin available in most of
Europe is not water soluble without the addition of an acid-
ifying agent such as lemon juice, vitamin C or citric acid.
The solution requires heat, which can kill contaminating
bacteria although may encourage spores from clostridial
infection to germinate [35]. Citric acid and vitamin C are
provided by most needle and syringe programmes (NSP),
given the risk of systemic candidiasis infections from use
of lemon juice [44]. It is crucial, however, that minimal
acidifier is used in injection preparation, because excess
citric acid use has been identified as a causal factor in
venous sclerosis and subsequent SSTI risk [41]. Clean
water to prepare injection solutions can be difficult to
access when injecting in constrained circumstances;
reports of saliva used as a water alternative in injection
preparation are concerning, given potential for severe
systemic infection [45].
The environment in which drugs are injected has
significant effects on frequency of sharing equipment,
materials used and infection risk. Injection in public places,
for example, can increase risk of venous trauma through
hurried injections and transitions to injecting in the
femoral vein to expedite ease of injection and hide injection
sites. A dearth of sterile injection equipment in most
custodial settings places individuals at risk of viral and
bacterial infections by necessitating equipment sharing.
Hospitals have also been identified as environments where
risky injection practices can take place, because of a lack of
timely opiate replacement therapy provision [42].
ASSESSMENT
Examination of infection sites is a crucial part of manage-
ment. Serious or unresolving injury to skin or infection in
tissue surrounding a vein or artery can present as local
pain, swelling, warmth and discolouration. Abscesses at
an injection site or in surrounding tissue, can be compara-
tively superficial and easily observed as a hot red swelling.
They may be or less obvious when deeper in subcutaneous
tissue ormuscle. Here, the diagnosis might bemore difficult
and general signs such as fever and nausea can require fur-
ther investigations such as ultrasound or soft tissue MRI
scanning. Visual examination may be enough to identify
the need for treatment, but caution is needed to prevent
progression to more serious conditions. Superficial skin in-
fections and infestations should be carefully diagnosed and
actively treated.
More general symptoms such as malaise, fever, nausea
and vomiting, and rigors caused by transient bacteraemia,
may indicate sepsis or generalised septicaemia. The pres-
ence of gangrene or deep sepsis may be suspected clinically
when there are skin changes, crepitus indicating gas under
the skin and a characteristic smell of a wound, associated
with clinical deterioration, high temperature toxicity, and
signs of systemic disease such as rigors, shock and renal
failure. The organism responsible may be identified and
confirmed by bacteriological sampling of material at the
site or by blood culture. As with other complications of
drug use, simple tests to detect anaemia, white cell count,
impaired renal function and blood‐borne virus screening
are part of any assessment.
The presence of swelling or groin pain in PWIDs raises
the clinical suspicion of thrombosis in a femoral vein
[46]. Preliminary investigations to exclude deep vein
thrombosis include aWell’s score and positive D‐dimer test,
to assess the presence of thrombosis, followed by venogra-
phy, ultrasound scanning and intra‐vessel angiography to
demonstrate deep vein thrombosis or soft tissue scanning
to measure the extent of abscess or deep‐seated infection
[47–49].
More severe consequences such as critical limb ischae-
mia from intra‐arterial injection may be more common
than reported [48]. Femoral artery aneurysms result from
damage to thewall of the blood vessel. Symptoms and signs
of vascular insufficiency in the lower limb include pain on
walking, or even at rest, loss of hair, mottling of the skin,
absent pulses and skin ulceration. Urgent assessment by
vascular specialist is required. Acute arterial insufficiency
can lead to tissue necrosis and, in extreme cases, gangrene
and limb amputation.
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TREATMENT AND PROGNOSIS
Although most skin and vascular complications are com-
mon and relatively easily managed, there are situations
that, because of late presentation, are likely to make diag-
nosis more difficult, treatment more complicated and the
outcome less favourable. Because infected injections sites
are common, they are usually self‐managed and, in most
cases, resolve with minimum adverse consequences.
Knowledge among PWID about SSTVI care and complica-
tions can be poor. Coupled with barriers to care, this can
result in practices such as lancing abscesses, obtaining
antibiotics from informal sources and poor adherence to
treatment [33,50]. Self management is not always as
protective as medical interventions and progressive and
cumulative damage to the vein is common.
The mainstay of treatment of SSTVIs is local hygiene
and dressing care combined with broad spectrum antibi-
otics. Cleaning injecting sites with alcohol pads or soap
and water is protective against skin infections. Adequate
provision of swabs and wipes for people who are street
injecting and/or unstably housed is important, because ac-
cess to clean water cannot be guaranteed [45]. Deeper in-
fections that show signs of spread beyond the original site
are usually treated with fluid and intravenous antibiotics.
Skin ulceration because of unresolved infection and ex-
acerbated by chronic venous insufficiency requires careful
management. Early nursing and medical care might avert
more serious consequences of infection. Complications
associated with delayed SSTVI care include septicaemia,
sepsis, gangrene, endocarditis, chronic venous ulcers
leading to surgical debridement, limb amputation, renal
failure and death.
Recurrence of SSTVIs among PWID is associated with
repeat hospital visits, poor antibiotic adherence, the need
for surgical intervention and hospital discharge against
medical advice. Primary care and community‐based inter-
ventions have been shown to reduce SSTVI‐related hospi-
tal admissions by as much as 35% and operating room
procedures by 70% [51].
Treatment of vein thrombosis may be by surgical
removal of the clot in the leg or, more commonly
anticoagulation with low molecular weight heparin or
warfarin in the acute phase of treatment, following on dur-
ing recovery a shorter or longer period of daily injections to
prevent a return of clotting in a traumatized vein [52–55].
In some cases, where the problem has been recurrent,
ongoing treatment with an anticoagulant may be neces-
sary for as long as injecting continues. This should be
weighed against the increased risk of anaemia and
prolonged bleeding after injection.
Incision and drainage are the most common surgical
interventions in treatment of injection site abscesses. The
diagnosis or suspicion of vasospasm may suggest a
diagnosis of temporary damage to blood flow rather than
thrombosis or endarteritis and indicate a non‐invasive
treatment [56].
The presence of cellulitis at an injection site may ini-
tially seem something to be treated with oral antibiotic
but diagnosis of a more invasive infection may lead to
necrotising fasciitis and clearly requires early and urgent
intervention.
For arterial problems, anticoagulation may be required
and surgical drainage of abscess or infection may be neces-
sary. Complications such as necrotising fasciitis may
require urgent surgical interventions. Operative treatment
uses procedures such as wide incision, subfascial examina-
tion, aggressive debridement and excision of necrosed
tissue. In more critical infections, or when irreversible limb
ischaemia is present, amputation of part or all of the limb
may be required. Rarely, contamination with gas and or-
ganisms (e.g. Clostridium perfringens or Clostridium novyi)
requires urgent tissue excision. Additional clinicalmanage-
ment includes oral or intravenous broad spectrum antibi-
otics, critical care support and reconstructive procedures
[57,58].
Pseudoaneurysm formation is a serious consequence of
injecting into an artery and is most common in the femoral
artery where proximity to the femoral vein makes it a com-
mon adverse risk. Pseudoaneurysms are less common, but
not unknown, in the upper limb [59]. For femoral aneu-
rysms vessel ligation is reported as the safest option with
a low amputation risk. A high proportion of patients have
subsequent longer term symptoms of circulation problems
such as venous insufficiency [60].
The complexity and extent of wound care may require
prolonged nursing care. This contact may allow the oppor-
tunity to engage the patient and build trust [61]. Engage-
ment is frequently associated with other interventions
such as medically assisted prescribing (opiate agonist
treatment) and syringe equipment programmes [62,63].
Advice can also include alternative, and potentially less
damaging, ways of using the substance such as smoking,
sniffing or by rectum (‘plugging’).
Technical opportunities for identifying veins for injec-
tion should be used at safer injecting facilities. This can
prevent unnecessary trauma and vein damage. Figures
3, 4, 5 and 6 illustrate the device used and demonstrate
the illumination of the veins in the hand. This can be used
to identify veins in other parts of the body and is available
in injecting room and heroin‐assisted treatment clinics.
Where injection cessation is required to obtain im-
provement, it is important to recognize how difficult this
may be for the individual involved. Support in switching
to other routes of administration, including though equip-
ment provision, can be helpful [64]. In case of a completely
deficient venous system, an extreme measure such as
insertion of a central venous catheter (CVC) to facilitate
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drug intake has been tried but this poses several practical
and ethical questions for the care givers. Such an interven-
tion in an exceptional situation still lacks data on
long‐term effects and cost benefits (Barbara Broers, per-
sonal communication).
Outcomes for skin and soft tissue infections are, inevita-
bly, variable and depend on a variety of factors and circum-
stances. Treated promptly and with proper expertise
recovery is usually achieved and damage minimised. Poor
outcomes depend on factors such as the constituency of
the infectious or toxic agent present, the delay before
intervention and the recurring nature of the traumatic
process. Access to sterile drugs and clean injecting equip-
ment has, in many localities, made a significant impact
on the problems described in this article.
OTHER CONSIDERATIONS RELATING TO
ASSESSMENT AND MANAGEMENT
Outreach services recognise the importance of early inter-
vention and support with injecting practices and access
to equipment. Limited access to injection supplies and
Figure 3 Veins in hand highlighted by detecting device [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 4 Veins in hand highlighted by detecting device [Colour figure can be viewed at wileyonlinelibrary.com]
Injecting drug use, the skin and vasculature 7
© 2020 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction Addiction
experiencing withdrawal are frequently reported barriers
to using risk reduction interventions [65]. Engaging mar-
ginalized people in care is increasingly recognized as an
area of policy and management importance [66,67].
People from more supported backgrounds with added
personal resources are likely to be able to avoid some of
these risk factors. Required initiatives include comprehen-
sive support for wound care, including provision of ban-
dages and dressings, education and equipment to support
injection site hygiene, safe injection preparation practices
and transitions from injecting, where desired. Initiatives
to reduce stigma toward PWID in hospital and other care
settings are crucial to enhance engagement. These can in-
clude employment of peer workers and cultural safety in-
formed training for health care professionals [68].
Among these newer initiatives are educational
programmes on wound care, injection site hygiene, equip-
ment provision and measures to be taken when problems
arise and early hospitalization for infection and sepsis
[69–73]. Needle and syringe availability are critical to the
prevention of vasculature problems either from inappropri-
ate equipment or contamination and tissue trauma from
Figure 5 Veins in hand highlighted by detecting device [Colour figure can be viewed at wileyonlinelibrary.com]
Figure 6 Vein locating device [Colour figure can be viewed at wileyonlinelibrary.com]
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reuse and sharing. The training of health care workers
is likely to help in conveying correct messages to drug
users.
The political and structural framework of drug control
and legislation has considerable impact on many
substance use related problems including vascular prob-
lems. Attention has been drawn to neglect of political
and policy interest into the causes and solutions for skin
and soft tissue infections and the importance of support-
ive interventions such as safe injecting environments
[62]. The rapid rise in opiate use and overdose in the
United States and the inadequate response to this
‘epidemic’ has contributed to an increase in use of illegal
opioids, injecting and subsequent sepsis complications
[74–76]. The impact of HIV/AIDS and hepatitis C
infection has had a significant effect on injection practices
and the delivery of services for PWID, highlighting the
importance of harm reduction [77].
Safer injecting facilities in sites such as Vancouver, Ge-
neva, Amsterdam, and a new heroin‐assisted treatment
clinics in Glasgow and Middlesbourgh are important to en-
gage people with care, including through implementation
of the broader programmes of health and social care inter-
ventions recommended by World Health Organization
[78]. In the United States, state laws have a significant im-
pact on NSP availability, with subsequent collateral dam-
age when this is restricted [75].
The need for integrated and robust support for PWID
includes mental and physical health and a
non‐judgemental approach to essential delivery of opiate
agonist treatment and injecting equipment. This is avail-
able in several countries around the world but often with
a limited range of services [66].
In conclusion, skin and vascular problems are frequent
in PWID and vary widely in severity in a constantly chang-
ing environment. The impact of COVID‐19 remains to be
seen but is likely to impact on service access, particularly
in relation to NSP access. Prevention includes access to
harm reduction measures such as sterile injection equip-
ment, a safe consumption environment, and education
on safe drug use and alternative ways of using drugs, and
access to drug treatment. Clinical examination for PWID
should include a respectful request to discuss safe injection
practices and to inspect injection sites including the groin
and the neck. Treatment of skin and vascular problems oc-
curs in the community and in specialist care facilities. All
social and medical care workers have a role to play in re-
ducing vascular harms. Engaging out‐of‐treatment and




Roy Robertson: Conceptualization; resources; writing‐orig-
inal draft. Barbara Broers: Conceptualization; resources;
writing‐original draft. Magdalena Harris: Conceptualiza-
tion; resources; writing‐original draft.
References
1. Harris M., Brathwaite R., McGowan C. R., Ciccarone D.,
Gilchrist G., McCusker M. et al. ’Care and Prevent’: rationale
for investigating skin and soft tissue infections and AA
amyloidosis among people who inject drugs in London. Harm
Reduct J 2018; 15: 23.
2. Rahimi‐Movaghar A., Noroozi A., Page K., Mohraz M.,
McFarland W., Malekafzali H. et al. Transition to and away
from injecting drug use among young drug users in Tehran,
Iran: a qualitative study. Iran J Psychiatry Behav Sci 2017;
11: e4561.
3. Larney S., Peacock A., Mathers B. M., Hickman M.,
Degenhardt L. A systematic review of injecting‐related injury
and disease among people who inject drugs. Drug Alcohol
Depend 2017; 171: 39–49.
4. Dahlman D., Berge J., Björkman P., Nilsson A. C., Håkansson
A. Both localized and systemic bacterial infections are
predicted by injection drug use: a prospective follow‐up
study in Swedish criminal justice clients. PLoS ONE 2018;
13: e0196944.
5. Hope V., Kimber J., Vickerman P., Hickman M., Ncube F.
Frequency, factors and costs associated with injection site
infections: findings from a national multi‐site survey of
injecting drug users in England. BMC Infect Dis 2008; 8: 120.
6. Hope V. Neglected infections, real harms: A global scoping of
injection‐related bacterial infections and responses. 2010.
89–96.
7. Hope V. D., Hickman M., Parry J. V., Ncube F. Factors associ-
ated with recent symptoms of an injection site infection or
injury among people who inject drugs in three English cities.
Int J Drug Policy 2014; 25: 303–7.
8. Lipsky B. A., Silverman M. H., Joseph W. S. A proposed new
classification of skin and soft tissue infections modeled on
the subset of diabetic foot infection. Open Forum Infect Dis
2016; 4: ofw255‐ofw.
9. Ciccarone D., Bourgois P. Explaining the geographical varia-
tion of HIV among injection drug users in the United States.
Subst Use Misuse 2003; 38: 2049–63.
10. Lewer D., Jayatunga W., Aldridge R. W., Edge C., Marmot M.,
Story A. et al. Premature mortality attributable to socioeco-
nomic inequality in England between 2003 and 2018: an
observational study. Lancet Public Health 2020; 5: e33–e41.
11. Summers P. J., Struve I. A., Wilkes M. S., Rees V. W. Injection‐
site vein loss and soft tissue abscesses associatedwith black tar
heroin injection: a cross‐sectional study of two distinct
populations in USA. Int J Drug Policy 2017; 39: 21–7.
12. Mars S. G., Bourgois P., Karandinos G., Montero F., Ciccarone
D. The textures of heroin: user perspectives on "Black tar" and
powder heroin in two U.S. cities. J Psychoactive Drugs 2016;
48: 270–8.
13. Mars S. G., Ondocsin J., Ciccarone D. Toots, tastes and tester
shots: user accounts of drug sampling methods for gauging
heroin potency. Harm Reduct J 2018; 15: 26.
14. Murphy E. L., DeVita D., Liu H., Vittinghoff E., Leung P.,
Ciccarone D. H. et al. Risk factors for skin and soft‐tissue
Injecting drug use, the skin and vasculature 9
© 2020 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction Addiction
abscesses among injection drug users: a case‐control study.
Clin Infect Dis 2001; 33: 35–40.
15. Rowe L., Cantwell A. Jr. Hypodermitis Sclerodermiformis:
successful treatment with ultrasound. Arch Dermatol 1982;
118: 312–4.
16. Andresz V., Marcantoni N., Binder F., Velten M., Alt M.,Weber
J. C., et al. Puffy hand syndrome due to drug addiction: a case‐
control study of the pathogenesis. Addiction 2006; 101:
1347–51.
17. Lewer D., Harris M., Hope V. Opiate injection‐associated skin,
soft tissue, and vascular infections, England, UK, 1997‐2016.
Emerg Infect Dis 2017; 23: 1400–3.
18. Swartz M. N. Clinical practice. Cellulitis N Engl J Med 2004;
350: 904–12.
19. Kilburn S. A., Featherstone P., Higgins B., Brindle R. Interven-
tions for cellulitis and erysipelas. Cochrane Database Syst Rev
2010; 6.
20. Karimi M., Ghaheri H., Assari S., Moghani Lankarani R.,
Moghani Lankarani M., Rafiey H. et al. Drug injection to sites
other than arm: a study of Iranian heroin injectors. Front
Psych 2014; 5: 23.
21. Maliphant J., Scott J. Use of the femoral vein (’groin injecting’)
by a sample of needle exchange clients in Bristol, UK. Harm
Reduct J 2005; 2: 6.
22. Mc G. C., Penrice G. M., Gruer L., Ahmed S., Goldberg D.,
Black M. et al. Lethal outbreak of infection with clostridium
novyi type a and other spore‐forming organisms in Scottish
injecting drug users. J Med Microbiol 2002; 51: 971–7.
23. Ramsay C. N., Stirling A., Smith J., Hawkins G., Brooks T.,
Hood J. et al. An outbreak of infection with bacillus anthracis
in injecting drug users in Scotland. Eurosurveillance 2010; 15:
19465.
24. Lappin J. M., Darke S., Farrell M. Stroke and methamphet-
amine use in young adults: a review. J Neurol Neurosurg
Psychiatry 2017; 88: 1079–91.
25. HuangM. C., Yang S. Y., Lin S. K., Chen K. Y., Chen Y. Y., Kuo
C. J. et al. Risk of cardiovascular diseases and stroke events in
methamphetamine users: a 10‐year follow‐up study. J Clin
Psychiatry 2016; 77: 1396–403.
26. Darke S., Ross J. The use of antidepressants among injecting
drug users in Sydney, Australia. Addiction 2000; 95:
407–17.
27. Darke S. The use of benzodiazepines among injecting drug
users. Drug Alcohol Rev 1994; 13: 63–9.
28. Sordo L., Indave B. I., Barrio G., Degenhardt L., de la Fuente
L., Bravo M. J. Cocaine use and risk of stroke: a systematic
review. Drug Alcohol Depend 2014; 142: 1–13.
29. Reneman L., Habraken J. B., Majoie C. B., Booij J., den Heeten
G. J. MDMA ("ecstasy") and its associationwith cerebrovascu-
lar accidents: preliminary findings. AJNR Am J Neuroradiol
2000; 21: 1001–7.
30. Kröger K., Ose C., Rudofsky G., Roesener J.,Weiland D., Hirche
H. Peripheral veins: influence of gender, body mass index, age
and varicose veins on cross‐sectional area. Vasc Med 2003; 8:
249–55.
31. Vuylsteke M. E., Colman R., Thomis S., Guillaume G.,
Degrande E., Staelens I. The influence of age and
gender on venous symptomatology. An epidemiological sur-
vey in Belgium and Luxembourg. Phlebology 2016; 31:
325–33.
32. Ki V., Rotstein C. Bacterial skin and soft tissue infections in
adults: a review of their epidemiology, pathogenesis, diagno-
sis, treatment and site of care. Can J Infect Dis Med Microbiol
2008; 19: 173–84.
33. Roose R. J., Hayashi A. S., Cunningham C. O. Self‐manage-
ment of injection‐related wounds among injecting drug
users. J Addict Dis 2009; 28: 74–80.
34. Morrison A., Elliott L., Gruer L. Injecting‐related harm and
treatment‐seeking behaviour among injecting drug users.Ad-
diction 1997; 92: 1349–52.
35. Seaton R. A. Skin and soft tissue infection: diagnosis andman-
agement. Clin Pharm 2009; 1: 13–22.
36. Brett M. M., Hood J., Brazier J. S., Duerden B. I., Hahné S. J.
Soft tissue infections caused by spore‐forming bacteria in
injecting drug users in the United Kingdom. Epidemiol Infect
2005; 133: 575–82.
37. Talan D. A., Moran G. J., Talan D. A., MoranG. J., Pinner R.W.
Update on emerging infections: news from the Centers for Dis-
ease Control and Prevention: tetanus among injecting‐drug
users—California, 1997. Ann Emerg Med 1998; 32: 385–6.
38. Wound botulism‐‐California, 1995. MMWR Morb Mortal
Wkly Rep 1995; 44: 889–92.
39. Corrin B., Nicholson A. G. Occupational, environmental and
iatrogenic lung disease. Pathology of the Lungs 2011327–99.
40. Scott R. N., Going J., Woodburn K. R., Gilmour D. G., Reid D.
B., LeibermanD. P. et al. Intra‐arterial temazepam.BMJ1992;
304: 1630.
41. Harris M., Scott J., Wright T., Brathwaite R., Ciccarone D.,
Hope V. Injecting‐related health harms and overuse of
acidifiers among people who inject heroin and crack
cocaine in London: a mixed‐methods study. Harm Reduct J
2019; 16: 60.
42. Harris M. Normalised pain and severe health care delay
among people who inject drugs in London: adapting cultural
safety principles to promote care. Soc Sci Med 2020; 260:
113183.
43. Craine N., Hickman M., Parry J. V., Smith J., McDonald T.,
Lyons M. Characteristics of injecting drug users accessing
different types of needle and syringe programme or using
secondary distribution. J Public Health 2010; 32: 328–35.
44. Servant J. B., Dutton G. N., Ong‐Tone L., Barrie T., Davey C.
Candidal endophthalmitis in Glaswegian heroin addicts:
report of an epidemic. Trans Ophthalmol Soc U K 1985; 104:
297–308.
45. Harris M., Scott J., Hope V.,Wright T., McGowan C., Ciccarone
D. Navigating environmental constraints to injection prepara-
tion: the use of saliva and other alternatives to sterile water
among unstably housed PWID in London. Harm Reduct J
2020; 17: 24.
46. Anand S. S., Wells P. S., Hunt D., Brill‐Edwards P., Cook D.,
Ginsberg J. S. Does this patient have deep vein thrombosis?
JAMA 1998; 279: 1094–9.
47. Schulz S., Beckenbach C., Philipp M., Hengstmann J. Color
coded duplex sonography of inguinal vessels in i.v. drug
addicts. Vasa 2002; 31: 7–13.
48. Woodburn K. R., Murie J. A. Vascular complications of
injecting drug misuse. Br J Surg 1996; 83: 1329–34.
49. Chong L. Y., Fenu E., Stansby G., Hodgkinson S. Management
of venous thromboembolic diseases and the role of
thrombophilia testing: summary of NICE guidance. BMJ: Br
Med J 2012; 344: e3979.
50. Smith M. E., Robinowitz N., Chaulk P., Johnson K. E. Self‐care
and risk reduction habits in older injection drug users with
chronic wounds: a cross‐sectional study. Harm Reduct J
2014; 11: 28.
51. Fernandez R., Griffiths R., Ussia C. Effectiveness of solutions,
techniques and pressure in wound cleansing. JBI Libr Syst
Rev 2004; 2: 1–55.
10 Roy Robertson et al.
© 2020 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction Addiction
52. Sampson F. C., Goodacre S., Kelly A. M., Kerr D. How is deep
vein thrombosis diagnosed and managed in UK and Austra-
lian emergency departments? Emerg Med J 2005; 22: 780–2.
53. Russell M., Dawson D. Best evidence topic report. Low molec-
ularweight heparin for intravenous drug users with deep vein
thrombosis. Emerg Med J 2004; 21: 711.
54. Mackenzie A. R., Laing R. B., Douglas J. G., Greaves M., Smith
C. C. High prevalence of iliofemoral venous thrombosis with
severe groin infection among injecting drug users in north
East Scotland: successful use of lowmolecular weight heparin
with antibiotics. Postgrad Med J 2000; 76: 561–5.
55. Russell M., Dawson D. Low molecular weight heparin for in-
travenous drug users with deep vein thrombosis. Emerg Med
J 2004; 21: 711.
56. Silverman S. H., Turner W. W. Jr. Intraarterial drug abuse:
new treatment options. J Vasc Surg 1991; 14: 111–6.
57. Chen J. L., Fullerton K. E., Flynn N. M. Necrotizing fasciitis as-
sociated with injection drug use. Clin Infect Dis 2001; 33:
6–15.
58. Callahan T. E., SchecterW. P., Horn J. K. Necrotizing soft tissue
infection masquerading as cutaneous abscess following illicit
drug injection. Arch Surg 1998; 133: 812–8.
59. SiuW. T., YauK. K., CheungH. Y., Law B. K., Tang C. N., Yang
G. P. et al. Management of brachial artery pseudoaneurysms
secondary to drug abuse. Ann Vasc Surg 2005; 19: 657–61.
60. Coughlin P. A., Mavor A. I. Arterial consequences of recrea-
tional drug use. Eur J Vasc Endovasc Surg 2006; 32: 389–96.
61. Nuttall R. Holistic care of a drug‐related wound: a case study
from a clinic for homeless people. Nurs Times 2009; 105:
18–21.
62. Phillips K. T., Stein M. D., Anderson B. J., Corsi K. F. Skin and
needle hygiene intervention for injection drug users: results
from a randomized, controlled stage I pilot trial. J Subst Abuse
Treat 2012; 43: 313–21.
63. Robinowitz N., Smith M. E., Serio‐Chapman C., Chaulk P.,
Johnson K. E. Wounds on wheels: implementing a specialized
wound clinic within an established syringe exchange
program in Baltimore, Maryland. Am J Public Health 2014;
104: 2057–9.
64. Harris M. An urgent impetus for action: safe inhalation inter-
ventions to reduce COVID‐19 transmission and fatality risk
among people who smoke crack cocaine in the United
Kingdom. Int J Drug Policy 2020102829.
65. Strathdee S. A., Patrick D. M., Currie S. L., Cornelisse P. G.,
Rekart M. L., Montaner J. S. et al. Needle exchange is not
enough: lessons from the Vancouver injecting drug use study.
AIDS 1997; 11: F59–F65.
66. Ho I. S., Holloway A., Stenhouse R. What do HIV‐positive
drug users’ experiences tell us about their antiretroviral
medication‐taking? An international integrated literature
review. Addiction 2020; 115: 623–52.
67. Kalk N. J., Robertson J. R., Kidd B., Day E., Kelleher M. J.,
Gilvarry E. et al. Treatment and intervention for opiate
dependence in the United Kingdom: lessons from triumph
and failure. Eur J Crim Policy Res 2018; 24: 183–200.
68. Pauly B. B., McCall J., Browne A. J., Parker J., Mollison A.
Toward cultural safety: nurse and patient perceptions of illicit
substance use in a hospitalized setting. ANS Adv Nurs Sci
2015; 38: 121–35.
69. Koester S. Copping, running, and paraphernalia Laws:
contextual variables and needle risk behavior among injec-
tion drug users in Denver. Hum Organ 1994; 53: 287–95.
70. Ng J., Sutherland C., Kolber M. R. Does evidence support su-
pervised injection sites? Can Fam Physician 2017; 63: 866.
71. Macpherson D. A Four‐Pillar Approach to Drug Problems in
Vancouver. 2001.
72. Gershon R. R. Infection control basis for recommending
one‐time use of sterile syringes and aseptic procedures for
injection drug users. J Acquir Immune Defic Syndr Hum
Retrovirol 1998; 18: S20–S24.
73. Phillips K. T., Altman J. K., Corsi K. F., Stein M. D. Develop-
ment of a risk reduction intervention to reduce bacterial
and viral infections for injection drug users. Subst Use Misuse
2013; 48: 54–64.
74. Annie F. H., Bates M. C., Uejio C. K., Bhagat A., Kochar T.,
Embrey S. The impact of the drug epidemic on the incidence
of sepsis in West Virginia. Cureus 2018; 10: e3521‐e.
75. Rudd R. A., Aleshire N., Zibbell J. E., Gladden R. M. Increases
in drug and opioid overdose deaths — United States,
2000–2014. Morb Mortal Wkly Rep 2016; 64: 1378–82.
76. Bauman Z. M., Morizio K., Singer M., Hood C. R., Feliciano D.
V., Vercruysse G. A. The heroin epidemic in America: a
Surgeon’s perspective. Surg Infect (Larchmt) 2019; 20:
351–8.
77. Des Jarlais D. C., McKnight C., Arasteh K., Feelemyer J.,
Perlman D. C., Hagan H. et al. Transitions from injecting to
non‐injecting drug use: potential protection against HCV
infection. J Subst Abuse Treat 2014; 46: 325–31.
78. Consolidated guidelines on HIV prevention, diagnosis, treatment
and care for key populations. Geneva: World Health Organiza-
tion; 2014 xix + 159.
Injecting drug use, the skin and vasculature 11
© 2020 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction Addiction
